Compare Novavax Inc (NVAX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Novo Nordisk A/S — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 169.6× Novavax Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | NVO | |
|---|---|---|
Market Cap | $1.30B | $220.53B |
Sector | Health | Health |
52-Week High | $11.19 | $71.70 |
52-Week Low | $6.22 | $35.29 |
Enterprise Value | $800.50M | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
